Journal of Clinical Medicine (Jun 2021)

Exercise Ventilatory Inefficiency in Post-COVID-19 Syndrome: Insights from a Prospective Evaluation

  • Álvaro Aparisi,
  • Cristina Ybarra-Falcón,
  • Mario García-Gómez,
  • Javier Tobar,
  • Carolina Iglesias-Echeverría,
  • Sofía Jaurrieta-Largo,
  • Raquel Ladrón,
  • Aitor Uribarri,
  • Pablo Catalá,
  • Williams Hinojosa,
  • Marta Marcos-Mangas,
  • Laura Fernández-Prieto,
  • Rosa Sedano-Gutiérrez,
  • Iván Cusacovich,
  • David Andaluz-Ojeda,
  • Blanca de Vega-Sánchez,
  • Amada Recio-Platero,
  • Esther Sanz-Patiño,
  • Dolores Calvo,
  • Carlos Baladrón,
  • Manuel Carrasco-Moraleja,
  • Carlos Disdier-Vicente,
  • Ignacio J. Amat-Santos,
  • J. Alberto San Román

DOI
https://doi.org/10.3390/jcm10122591
Journal volume & issue
Vol. 10, no. 12
p. 2591

Abstract

Read online

Introduction: Coronavirus disease 2019 (COVID-19) is a systemic disease characterized by a disproportionate inflammatory response in the acute phase. This study sought to identify clinical sequelae and their potential mechanism. Methods: We conducted a prospective single-center study (NCT04689490) of previously hospitalized COVID-19 patients with and without dyspnea during mid-term follow-up. An outpatient group was also evaluated. They underwent serial testing with a cardiopulmonary exercise test (CPET), transthoracic echocardiogram, pulmonary lung test, six-minute walking test, serum biomarker analysis, and quality of life questionaries. Results: Patients with dyspnea (n = 41, 58.6%), compared with asymptomatic patients (n = 29, 41.4%), had a higher proportion of females (73.2 vs. 51.7%; p = 0.065) with comparable age and prevalence of cardiovascular risk factors. There were no significant differences in the transthoracic echocardiogram and pulmonary function test. Patients who complained of persistent dyspnea had a significant decline in predicted peak VO2 consumption (77.8 (64–92.5) vs. 99 (88–105); p p p = 0.001), and quality of life (KCCQ-23 60.1 ± 18.6 vs. 82.8 ± 11.3; p O2 slope 32 (28.1–37.4) vs. 29.4 (26.9–31.4); p = 0.022) and high PETCO2 (34.5 (32–39) vs. 38 (36–40); p = 0.025). Interpretation: In this study, >50% of COVID-19 survivors present a symptomatic functional impairment irrespective of age or prior hospitalization. Our findings suggest a potential ventilation/perfusion mismatch or hyperventilation syndrome.

Keywords